NCT00477945View on ClinicalTrials.gov

Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Non Hodgkin's Lymphoma
Interventions
DRUG

clofarabine

"Cohort N Clofarabine (mg/m2/day)~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Indiana University School of Medicine

OTHER

NCT00477945 - Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL | Biotech Hunter | Biotech Hunter